ALK7: A Key Molecule in TGF-β Superfamily Type I Receptor and Metabolic Regulation Research

Author: Senior Product Manager of UA Views：10

This article focuses on the molecular characteristics and biological functions of ALK7 (ACVR1C), systematically elaborating its gene localization, protein domain composition, and receptor complex assembly mechanisms as a type I receptor of the TGF-β receptor superfamily, analyzing the metabolic functional positioning of Activin E in regulating adipocyte lipolysis through the ALK7-SMAD2/3 axis, and clarifying the essential differences between ALK7 and anaplastic lymphoma kinase (ALK) in terms of gene origin, molecular structure, and disease association.

Recent Advances
Product Information

Recent Advances

ALK7: A Key Molecule of the TGF-β Superfamily Type I Receptor in Metabolic Regulation Research

Summary: This article focuses on the molecular characteristics and biological functions of ALK7 (ACVR1C), systematically describing its gene localization, protein domain composition, and receptor complex assembly mechanisms as a Type I receptor of the TGF-β receptor superfamily. It analyzes the metabolic functional positioning of Activin E in regulating adipocyte lipolysis through the ALK7-SMAD2/3 axis, and clarifies the essential differences between ALK7 and anaplastic lymphoma kinase (ALK) in terms of gene origin, molecular structure, and disease association.

I. Gene Localization and Molecular Identity Definition of ALK7.

ALK7, officially named ACVR1C (activin A receptor type 1C), is a Type I receptor member of the TGF-β receptor superfamily. It must first be clarified that ALK7 and anaplastic lymphoma kinase (ALK) are two completely different molecules: the ALK gene is located in the human chromosome 2p23.2 region and encodes a 1620-amino-acid receptor tyrosine kinase, named for its discovery in 1994 as an NPM-ALK fusion protein in anaplastic large cell lymphoma; whereas ALK7 is encoded by the ACVR1C gene and belongs to the serine/threonine kinase receptor family. Although the two share the "ALK" prefix in nomenclature, their gene origins, kinase categories, ligand systems, and disease associations are entirely distinct. This distinction is a prerequisite for avoiding confusion when reading ALK7 research literature.

II. Protein Structure and Receptor Complex Assembly of ALK7.

ALK7 belongs to the Type I receptor family of the TGF-β receptor superfamily, and its protein structure comprises an extracellular ligand-binding domain, a single transmembrane region, and an intracellular serine/threonine kinase domain. Unlike receptor tyrosine kinases such as ALK, ALK7 does not possess tyrosine kinase activity but serves as a Type I receptor participating in transmembrane transduction of TGF-β family signals. Upon ligand binding, 2 Type I receptors and 2 Type II receptors assemble into a "dimer of dimers" tetrameric receptor complex, in which the Type II receptor phosphorylates and activates the GS domain of ALK7, thereby initiating downstream SMAD2/3 signaling. This receptor assembly mode determines that ALK7 activation depends on the precise spatial pairing of Type I and Type II receptors, and also explains why interventions targeting this pathway can achieve selectivity at the Type I receptor level or produce mechanistic overlap at the Type II receptor level.

III. Functional Positioning of ALK7 in the Activin E Signaling Axis.

ALK7 is a key receptor connecting liver-derived signals with adipose tissue lipolysis regulation. INHBE is mainly expressed in the liver, and its encoded βE subunit forms a dimer, Activin E, which is secreted into the circulation. Activin E activates SMAD2/3 signaling through the receptor complex on the surface of adipocytes, inhibits PPARγ-related transcriptional programs, reduces adipocyte lipolysis capacity, and promotes lipid storage and adipocyte hypertrophy. ALK7 in this pathway assumes the core function of receiving circulating Activin E signals and initiating the intracellular cascade. The classical pro-lipolytic signal in adipocytes is mediated by β-adrenergic receptors, which promote lipolysis by elevating cAMP levels, activating PKA, and phosphorylating proteins such as HSL and Perilipin, whereas the ALK7-SMAD2/3 pathway exerts a negative regulatory effect on lipolysis. Therefore, the common pharmacological goal of targeting ALK7 is to attenuate this inhibitory signal and promote fat mobilization, thereby achieving fat reduction.

IV. Tissue Expression and Targeted Delivery Characteristics of ALK7.

Tissue expression determines the delivery requirements of the two targeting strategies. INHBE has a relatively clear liver expression profile and can be delivered to hepatocytes using GalNAc-conjugated siRNA; ALK7-targeting siRNA, however, needs to enter adipocytes, and adipose tissue delivery is technically more challenging. Tissue expression data support strong RNA enrichment of ALK7 in adipose tissue, providing a target-expression basis for adipocyte delivery. In terms of signal coverage, silencing INHBE reduces circulating ligand levels, which theoretically can affect all tissues expressing ALK7 receptors; whereas silencing ACVR1C reduces local receptor expression in adipocytes, with a scope of action more confined to adipose tissue itself, but it can cover ALK7 receptor signaling including that of other ligands.

V. Human Genetic Evidence and Drug Development Value of ALK7.

In 2022, based on exome sequencing data from 362,679 participants of European ancestry in the UK Biobank, researchers analyzed the association between rare coding variants and BMI-adjusted waist-to-hip ratio; in the same year, another study integrated data from UK, Swedish, and Mexican cohorts totaling 618,375 individuals, including 160,058 participants of non-European ancestry. Both studies identified genes related to fat distribution, including INHBE and ACVR1C. Among them, loss-of-function variants in INHBE were associated with lower BMI-adjusted waist-to-hip ratio, providing directional evidence for drug development targeting this gene. ACVR1C was independently identified as a receptor gene in the same pathway, supporting at the human genetics level the causal role of the signaling axis in which ALK7 resides in the regulation of fat distribution. It is worth noting that drugs targeting ActRIIA/ActRIIB and blocking ligand binding share mechanistic overlap with the Activin E/ALK7 pathway at the Type II receptor level, but their effects also involve ligands such as myostatin and Activin A, and therefore are not equivalent to specific inhibition of ALK7.

VI. Conclusion.

ALK7, as a Type I receptor of the TGF-β receptor superfamily encoded by the ACVR1C gene, has become a highly regarded emerging target in the field of metabolic diseases, especially obesity treatment, by virtue of its essential distinction from anaplastic lymphoma kinase in gene origin and kinase category, its molecular mechanism of assembling tetrameric complexes with Type II receptors and initiating SMAD2/3 signaling, its core functional positioning in connecting liver-derived Activin E signals with adipocyte lipolysis inhibition, the delivery feasibility supported by adipose tissue RNA enrichment, and the independent identification of ACVR1C by large-scale human genetics such as the UK Biobank.

In basic research on ALK7 receptors and drug development for metabolic diseases, high-quality recombinant ALK7 protein is a core tool for dissecting its ligand-binding mechanisms with Activin E, evaluating receptor complex assembly, and screening targeted intervention molecules. The GST tag facilitates efficient purification via glutathione affinity chromatography and can serve as a detection tag for analyses such as enzyme-linked immunosorbent assay and surface plasmon resonance. To meet the needs of ALK7 functional research and obesity therapeutic drug development, Uprotein provides ACVR1C(ALK7) GST Tag Protein, Human. This product is suitable for applications including binding activity analysis of ALK7 with Activin E and Type II receptors, research on ALK7-mediated SMAD2/3 signaling pathway activation, in vitro evaluation of small nucleic acid drugs and receptor blockers targeting ACVR1C, and exploration of INHBE/ALK7 pathway mechanisms.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next